PARP Inhibitors for Cancer Therapy

Ken Yu Lin, W. Lee Kraus

Research output: Contribution to journalShort survey

32 Citations (Scopus)

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Original languageEnglish (US)
Number of pages1
JournalCell
Volume169
Issue number2
DOIs
StatePublished - Apr 6 2017
Externally publishedYes

Fingerprint

Mutation
Poly(ADP-ribose) Polymerases
Transcription
DNA Replication
DNA Repair
Ovarian Neoplasms
Neoplasms
Repair
Cells
DNA
Therapeutics
Pharmaceutical Preparations
Poly(ADP-ribose) Polymerase Inhibitors
rucaparib
olaparib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

PARP Inhibitors for Cancer Therapy. / Lin, Ken Yu; Kraus, W. Lee.

In: Cell, Vol. 169, No. 2, 06.04.2017.

Research output: Contribution to journalShort survey

Lin, Ken Yu ; Kraus, W. Lee. / PARP Inhibitors for Cancer Therapy. In: Cell. 2017 ; Vol. 169, No. 2.
@article{b4a8e0870cc84fa188833ca340fb281a,
title = "PARP Inhibitors for Cancer Therapy",
abstract = "Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.",
author = "Lin, {Ken Yu} and Kraus, {W. Lee}",
year = "2017",
month = "4",
day = "6",
doi = "10.1016/j.cell.2017.03.034",
language = "English (US)",
volume = "169",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - PARP Inhibitors for Cancer Therapy

AU - Lin, Ken Yu

AU - Kraus, W. Lee

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

AB - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

UR - http://www.scopus.com/inward/record.url?scp=85016957959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016957959&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.03.034

DO - 10.1016/j.cell.2017.03.034

M3 - Short survey

C2 - 28388401

AN - SCOPUS:85016957959

VL - 169

JO - Cell

JF - Cell

SN - 0092-8674

IS - 2

ER -